Clinical Trial

A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)

Study acronym: B-SUPREME
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-04-30; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2025-07-25
Trial Details
NCT Number NCT06963710
Lead Sponsor Aligos Therapeutics
Conditions Chronic Hepatitis B Infection
Enrollment 200 participants
Start Date 2025-07-15
Primary Completion 2027-03 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-05-01